Bacteria transplant with standard therapy for rectal cancer
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests whether transplanting healthy gut bacteria, along with standard chemotherapy and radiation before surgery, can help shrink tumors and improve outcomes in people with a specific type of rectal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are generally healthy and able to care for yourself (ECOG score 0-1).
- Your tumor is within 12 cm of the anal opening and can likely be completely removed with surgery.
- Your cancer is not a type with high microsatellite instability (MSS/pMMR) and does not have RAS or BRAF gene changes.
- You have not had any prior cancer treatment, including surgery, chemo, radiation, or immunotherapy.
- You do not have active autoimmune diseases, inflammatory bowel disease, or serious infections.
- You are able to take precautions to avoid pregnancy during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.